727993-33-1

Usage

Uses

Used in Pharmaceutical Industry:
6-Methoxy-2-trifluoromethyl-3-nitropyridine is used as a key intermediate in the synthesis of pyrazinones, which are known as corticotropin-releasing factor-1 (CRF1) receptor antagonists. These antagonists play a crucial role in the treatment of stress-related disorders, such as anxiety, depression, and post-traumatic stress disorder (PTSD), by modulating the activity of the hypothalamic-pituitary-adrenal (HPA) axis.
In the synthesis process, 6-Methoxy-2-trifluoromethyl-3-nitropyridine undergoes a series of chemical reactions, including nucleophilic substitution, reduction, and cyclization, to form the desired pyrazinone derivatives. The presence of the methoxy, trifluoromethyl, and nitro groups in the molecule contributes to the overall biological activity and selectivity of the resulting CRF1 receptor antagonists.
Furthermore, the unique structural features of 6-Methoxy-2-trifluoromethyl-3-nitropyridine, such as the electron-withdrawing trifluoromethyl group and the electron-donating methoxy group, can be exploited to fine-tune the physicochemical properties and pharmacokinetic profile of the synthesized pyrazinone derivatives. This allows for the development of more potent and selective CRF1 receptor antagonists with improved safety and efficacy profiles.

InChI:InChI=1/C7H5F3N2O3/c1-15-5-3-2-4(12(13)14)6(11-5)7(8,9)10/h2-3H,1H3

Upstream product

• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 1514-87-0 metyhyl chlorodifluoroacetate 
• 75-61-6 dibromodifluoromethane 

Downstream Products

• 503184-37-0 2'-benzyloxy-6-methoxy-3'-nitro-2-trifluoromethyl-[3,4']bipyridinyl 
• 503184-34-7 3-iodo-6-methoxy-2-(trifluoromethyl)pyridine 
• 727993-34-2 6-methoxy-2-(trifluoromethyl)pyridin-3-amine 

Relevant academic research and scientific papers

Therapeutically Active Thiazolo-Pyrimidine Derivatives

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Heterocyclic cyclopropyl-substituted FXR binding compounds

The present invention relates to compounds defined by formula (I): or an enantiomer, diastereomer, tautomer, solvate or pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently from each other selected from hydro

Heterocyclic FXR binding compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula I,or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF, receptor antagonists. Compounds of the invention are useful for t

HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine.

A series of imidazo[4,5-b]pyridines with a 7-(3-pyridyl) substituent is described as high affinity CRF receptor ligands. Individual analogues were synthesized from key intermediates obtained via palladium-catalyzed coupling of 3-pyridyl zinc or boronic acid organometallic intermediates with 2-benzyloxy-4-chloro-3-nitropyridine 12.